ASCO 2022

Transatlantic differences in ADC side effects…

What are the cosenquences of the new OS data for CDK4/6…

Paradigm shift in breast cancer: Where do we use the…

More data needed: Are the results clinical meaningful?…

How to determine progress of disease? How to proceed…

Patients perspectives: ADCs - how do manage the new,…

ADCs & CDK4/6i - paradigm shifts and therapy switches…

Determining HER2 receptor expression: How do we target…

Palbociclib - Overall survival data

No changes in clinical practice after new CDK4/6i-data

New SoC for large subpopulation of breast cancer…

Combi SERD + Palbo reduces proliferation better than…

Option for overcoming endocrine resistance?

Endocrine therapy alone is important in treatment of…

Sacituzumab govitecan improves PCr in patients with…

Oligometastasis: no advantage of additional…

Possible explanations of the negative study

SG may be a good option for pre-treated HR+/Her2- pts

Smart chemotherapy improves PFS

ADC: future therapeutic option in advanced HR+/HER2 BC

Disappoiting final OS data and its implications for our…

Exciting and practice changing news for HR+/Her2low MBC…

New agents for the clincial practice

Gamechanger in breast cancer

Benefit of CDK4/6 Switch after Progression

First evidence on benefit of CDK4/6 inhibitors beyond…

Impressive and practice changing data of ADCs mark the…

My ASCO22 highlights in metastatic breast cancer

Additional administration of ribociclib improves PFS…

Practice changing data

Exciting advances across a wide subset of breast…

Revolution in the field of HR+ disease

New standard of care for HR+/Her2low patients

Improvment of PFS & OS with activated alteration…

Good therapeutic option in HR+ HER2- mBC after failure…

Discontiunation of trial is disappointing despite…

Fascinating data of ADCs in breast cancer at ASCO22

Breakthrough news with antibody drug conjugate

No effect for local treatment of metastasis

Patritumab Deruxtecan: HER3-targeted ADC in HER3…

Combination of ctDNA and TKa assesment may improve…

T-DxD should be the new SoC for Her2low MBC patients

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Novità entusiasmanti e practice changing per le…

I nuovi impressionanti risultati degli ADC a l’ASCO…

Nowy standard dla znaczącej subopulacji chorych na raka…

Il sacituzumab govitecan migliora il PFS nei tumori…

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…

ADCs en cáncer de mama con receptores hormonales…

Una rivoluzione per il tumore mammario…

SG come nuova opzione di cura per le pazienti con…

Noutăți inovatoare cu conjugatul de medicamente cu…

La valutazione combinata di ctDNA e TKa può aiutare a…

CT benefit for elderly patients, if they are able to…

Long term overall survival benefit of Denosumab in…

Adding towards deescalation in luminal A EBC by…

Ovarian function suppression - it is here to stay!

High concordance of local, central IHC and RT-PCR for…

Combi SERD + Palbo redzuert proliferation better than…

Molecular landscape - Part 1

Immunotherapy - Part 2

Molecular landscape - Part 2

COSMIC-021: Not practice-changing, but interesting…

New treatment options for METexon 14 skipping:…

New components and therapies for advanced NSCLC

Strategies for PD-L1 > 50%

Options after progression to chemo/IO and for KRASG12C…

Promising results for pre-treated patients with…

A chemo-free option in patients with EGFR-mutation

KRASG12C mutation: Adagrasib is comparabale to…

Amivantamab as a future option for METex14 patients?

New option in patients harboring METex14 mutation

PD-L1 over 50%: Chemo-IO or IO?

CLN-081 for patients with metastatic NSCLC and an…

Bispecific Antibodies - the cMET field is moving

In the second line: Options for Immunotherapy…

Multiple aquired resistance mutations may drive disease…

Role of IO and chemo-IO in patients with PD-L1 > 50%

Is adagrasib an alternative to sotorasib?

Bispezifische Antikörper - Neues von CHRYSALIS

Was tun nach Versagen einer Chemoimmun-Therapie?

PD-L1 über 50 % - was tun?

Segunda Linea: opciones tras resistencia a…

CLN-081 voor patienten met gemetastaseerd NSCLC en een…

Nuevas terapias para el CPCNP avanzado

Nieuwe behandelopties voor METexon 14 skipping:…

COSMIC-021: Nicht praxisverändernd, aber interessante…

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…

Veelbelovende resultaten voor voorbehandelde patienten…

Une nouvelle option, l’amivantamab, en situation de…

Neoadjuvant and adjuvant therapy - Part 1

A new option in neoadjuvant chemoimmunotherapy

New treatment approaches in Stage III

Perspectives on multimodality

CheckMate-816: Neoadjuvant therapy

Neue Ansätze im Stadium III

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…

SKYSCRAPER-02: Subgroups could be important

No benefit for tiragolumab / novel anti-PD-1 mAB…

mHSPC: Transatlantic differences in genetic testing &…

mCRPC: LuPSMA - new treatment option in mCRPC

The efficacy of doublets in mHSPC

PFS good surrogate endpoint for overall survival

Frequent imaging for early detection of metastases in…

Surrogate endpoints in mHSPC

GGT impacts PCa patients care

No big scoop, but encouraging results

Ongoing trial invetiagting the impact of…

Value of triple-therapy - complimentary study to…

Lu-PSMA in the third line

SUVmean is highly predictive of better PFS and OS

LuPSMA & cabazitaxel are better than SoC alone

The highlights in GU cancers of ASCO22

Lu-PSMA effective regardless of prior or concomitant…

Phase 1 study on combining LuPSMA treatment with…

SHR3680 - do we need a new androgen receptor inhibitor

SUV mean at PET images as a prognostic tool for PSMA…

Further updates from the VISION trial

3 year overall survival of TheraP study

TheraP shows no difference in overall survival between…

ADT alone is no longer standard of care

Pas de nouvelles sensationnelles mais des données…

Lo mas destacado en tumores GU en ASCO 2022

Treårs överlevnadsresultat i TheraP studien.

Tidigare endpoints I mHSPC studier

Kvantifiering av PMSA PET upptaget som prognostisk…

Combination Therapy is State of the Art in Metastatic…

The relevance of quality of life in kidney cancer!

What are the consequences for future trial design?

Depth of remission in firstline

Combi Axi + Pembro also successful with good risk…

Clear evidence for durable benefit for patients with…

Belzutifann shows good tumor activity in renal cancer

Importance of health related quality of life

The highlights in GU cancers of ASCO22

Should we be looking at Everolimus in the future?

Should Everolimus be revisited for high-risk patients?

PSMA-PET may improve imaging of clear cell RCC

Pas de nouvelles sensationnelles mais des données…

The role of systemic treatment in the pre-operative…

ADCs: do we enter a new era of therapy for urothelial…

The highlights in GU cancers of ASCO22

ADCs: News from ASCO 2022

My highlights in localized urothelial cancer

Investigating sasanlimab in BCG-unresponsive NMIBC

Exciting future for ADCs

The end of of VEGF-targeted therapy in urothelial…

Maintenance concepts

No big scoop, but encouraging results

My highlights of metastasized urothelial cancer

Perioperative immuno-chemotherapy in MIBC

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το…

Opportunities & challenges of cancer genetics

Few testicular tumors after 5 years

Radiotherapy as a new standard for cisplatin ineligible…

Systemic therapy

News from Sarcoma